| Similar Articles |
|---|
 |
The Motley Fool
September 22, 2006
Brian Lawler |
Hospira's New Mate Down Under The specialty injectable pharmaceutical announces an acquisition, but the move means adding on a lot more debt. Investors, take note.   |
The Motley Fool
August 8, 2007
Ryan Fuhrmann |
Hospira Looks to Deliver Will a recent acquisition boost drug delivery firm Hospira's growth prospects? The new Mayne Pharma Limited division played a primary role in delivering an impressive 30% reported sales growth. |
The Motley Fool
November 9, 2006
Brian Lawler |
Hospira's Flatlining Sales There's no good news to be found in this medical products supplier's medicine chest. The upcoming fourth quarter isn't going to be any better, either. Investors, take note. |
The Motley Fool
August 10, 2006
Stephen D. Simpson |
Volatility, Thy Name Is Hospira Margins continue to stand in the way of consistent performance at the health-care company. Investors, take note. |
The Motley Fool
June 2, 2005
Brian Gorman |
Hospira's Little Purchase There may be more to Hospira's recent acquisition than meets the eye. |
The Motley Fool
March 1, 2006
Brian Gorman |
Hospira's Stumble In spite of an unsightly quarter, good things still are happening at this medical products and services outfit. Investors, take note. |
The Motley Fool
January 20, 2011
Jeremy Phillips |
Time to Sell Hospira? Hospira has failed two of the quick tests that would make it a sell. This is great, but does it mean you should hold your Hospira shares? |
The Motley Fool
May 9, 2006
Stephen D. Simpson |
Riding the Hospira Yo-Yo There's a solid foundation on this roller coaster pharmaceutical and drug delivery company. Maybe Hospira's current valuation doesn't make it a "gem," but that's not really within its control. |
The Motley Fool
May 13, 2005
Brian Gorman |
Hospira's Hopeful Signs The medical products company's strong quarter belies a less exciting future. Investors should probably take a wait-and-see attitude. |
The Motley Fool
October 20, 2005
Stephen D. Simpson |
Baxter Needs Growth Infusion This is a fine health-care company, but a sluggish top line suggests there are limits to how far it can go. Trading at nearly 20 times forward earnings, it seems like expectations of a growth revival are already in the stock. |
The Motley Fool
November 20, 2006
Brian Gorman |
Hospira's Bold Move The drug delivery outfit's stab at biosimilars is worth some attention, but investors shouldn't assume a major payoff. |
The Motley Fool
November 11, 2004
Brian Gorman |
Hospira's Possibilities The medical products and services outfit is not flashy, but it may benefit from long-term trends. Their stock may be worth monitoring. |
BusinessWeek
May 31, 2004
Robert Barker |
Hospira Just May Put You In The Pink If the Abbott Laboratories spin-off's first steps hardly seem promising, that's one reason why I see the company as worth much more of the intelligent investor's attention than the long calendar of pending tech and biotech IPOs. |
The Motley Fool
November 10, 2005
Stephen D. Simpson |
Hospitable Treatment for Hospira Solid margins fuel strong earnings at the hybrid generics - medical distributor. Buying this stock wisely may be the key to good long-term returns. |
The Motley Fool
April 29, 2011
Brian Orelli |
Show Us the Money, Drugmakers Drugmakers have cash and they aren't afraid to use it -- on themselves. |
Pharmaceutical Executive
August 1, 2011
Peter Houston |
Google+ and Pharma Is Google+ the social media platform that pharma has been waiting for? |
The Motley Fool
January 5, 2010
Brian Orelli |
A Deal Manufactured by Necessity Genzyme gets some help from a new friend. |
The Motley Fool
January 18, 2012
Sean Williams |
Are These 2 Medical Device Makers Takeover Targets? Could these two medical device makers put themselves up for sale in 2012? |
The Motley Fool
August 8, 2011
Seth Jayson |
Why the Street Should Expect Big Things from Hospira Although Hospira shows inventory growth that outpaces revenue growth, the company may also display positive inventory divergence, suggesting that management sees increased demand on the horizon. |
Chemistry World
February 12, 2015
Rebecca Trager |
Hospira buyout is a shot in the arm for Pfizer's biosimilars Pfizer said in a statement that its acquisition of Hospira will create 'a leading global sterile injectables business. |
IndustryWeek
September 1, 2006
David Blanchard |
Hospira CEO Chris Begley -- Diagnosis: Green and Lean Chris Begely says manufacturers should become more environmentally responsible. What's more, he's doing something about it. |
The Motley Fool
January 31, 2006
Stephen D. Simpson |
Guidance Puts ICU Medical in the Trauma Ward This oft-volatile stock had a strong fourth quarter, but weak guidance. Even with today's steep drop in price, the shares aren't cheap enough to be interesting. |
The Motley Fool
November 9, 2005
Stephen D. Simpson |
Fishing for Value at Fisher Even with today's earnings-induced jump, there still might be some value here at researcher Fisher Scientific. Investors, take note. |
The Motley Fool
December 31, 2010
Brian Orelli |
How the Other Half of Pharma Lives A dive into spec pharma. |
